630-93-3

Basic information

• Product Name: Phenytoin sodium
• Synonyms: solantoin;solantyl;solublephenytoin;tacosal;5,5-Diphenylhydatoin sodium salt;5,5-Diphenyl-2,4;PHENYTOINUM NATRICUM;2,4-Imidazolidinedione, 5,5-diphenyl-, monosodium salt
• CAS NO: 630-93-3
• Molecular Formula: C₁₅H₁₁N₂O₂*Na
• Molecular Weight: 274.25
• EINECS: 211-148-2
• Product Categories: Classes of Metal Compounds;Na (Sodium) Compounds (excluding simple sodium salts);Typical Metal Compounds;Sodium channel;API intermediate;RONDOMYCIN
• Mol File: 630-93-3.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 428.2 °C at 760 mmHg
• Flash Point: 212.8 °C
• Appearance: White to almost white/Crystalline Powder
• Storage Temp.: Inert atmosphere,Room Temperature
• Solubility: aqueous base: soluble
• Merck: 14,7322
• CAS DataBase Reference: Phenytoin sodium(CAS DataBase Reference)
• NIST Chemistry Reference: Phenytoin sodium(630-93-3)
• EPA Substance Registry System: Phenytoin sodium(630-93-3)

Safety Data

• Hazard Codes: Xn
• Statements: 22-43-62-63
• Safety Statements: 22-36/37/39-45
• RIDADR: UN 2811 6.1/PG 3
• WGK Germany: 3
• RTECS: MU1400000
• HazardClass: 6.1(b)
• PackingGroup: III
• Hazardous Substances Data: 630-93-3(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 630-93-3 differently. You can refer to the following data:
1. antibacterial
2. Antiepileptic
3. 5,5-Diphenylhydantoin sodium salt has been used:in the cream preparation for treating burn woundsin seizure behavior testing as an anticonvulsant in Drosophilain in vivo embryo toxicity test in mouse embryonic stem cells

Brand name

Diphenylan (Lannett); Phenytek (Mylan); Phenytex (Watson) [Name previously used: Diphenylhydantoin Sodium.].

General Description

Phenytoin sodium, 5,5-diphenyl-2,4-imidazolidinedione, 5,5-diphenylhydantoin,diphenyl-hydantoin sodium (Dilantin), has been used fordecades in the control of grand mal types of epilepticseizure. It is structurally analogous to the barbiturates butdoes not possess their extensive sedative properties. Thecompound is available as the sodium salt. Solutions for parenteraladministration contain 40% propylene glycol and10% alcohol to dissolve the sodium salt.

Clinical Use

Phenytoin sodium’s cardiovascular effects were uncoveredduring observation of toxic manifestations of the drugin patients being treated for seizure disorders. Phenytoinsodium was found to cause bradycardia, prolong the PRinterval, and produce T-wave abnormalities on electrocardiograms.It is a class IB antiarrhythmic agent. Today,phenytoin sodium’s greatest clinical use as an antiarrhythmicdrug is in the treatment of digitalis-induced arrhythmias.34 Its action is similar to that of lidocaine. It depressesventricular automaticity produced by digitalis, without adverseintraventricular conduction. Because it also reversesthe prolongation of AV conduction by digitalis, phenytoinsodium is useful in supraventricular tachycardias caused bydigitalis intoxication.

Safety Profile

Confirmed carcinogen. Experimental teratogen. Other experimental reproductive effects. Poison by ingestion, subcutaneous, intravenous, and intraperitoneal routes. Human systemic effects by ingestion: anorexia, respiratory depression, nausea or vomiting, hemorrhage, dermatitis, and endocrine effects. Mutation data reported. An anticonvulsant and cardiac depressant used for the treatment of grand mal and psychomotor seizures. When heated to decomposition it emits very toxic fumes of NOx and Na2O.

InChI:InChI=1/C15H12N2O2.Na/c18-13-15(17-14(19)16-13,11-7-3-1-4-8-11)12-9-5-2-6-10-12;/h1-10H,(H2,16,17,18,19);

Upstream product

• 119-53-9 2-hydroxy-2-phenylacetophenone 
• 57-41-0 phenythoin 

Downstream Products

• 27512-05-6 3-benzyloxymethyl-5,5-diphenylhydantoin 
• 27512-00-1 3-methoxymethyl-5,5-diphenylhydantoin 
• 1053-09-4 3-benzoyl-5,5-diphenylhydantoin 
• 1418003-58-3 3-{2-[2-(morpholin-4-yl)ethoxy]ethyl}-5,5-diphenylimidazolidine-2,4-dione 
• 1418003-56-1 2-{2-[2-(2,5-dioxo-4,4-diphenylimidazolidin-1-yl)ethoxy]ethoxy}ethyl-4-methylbenzenesulphonate 
• 1418003-55-0 2-[2-(2,5-dioxo-4,4-diphenylimidazolidin-1-yl)ethoxy]ethyl-4-methylbenzenesulphonate 
• 1418003-61-8 3-{2-[2-(4-(4-chlorophenyl)piperazin-1-yl)ethoxy]ethyl}-5,5-diphenylimidazolidine-2,4-dione 
• 1418003-60-7 3-{2-[2-(4-phenylpiperazin-1-yl)ethoxy]ethyl}-5,5-diphenylimidazolidine-2,4-dione 
• 1418003-59-4 3-{2-[2-(piperidin-1-yl)ethoxy]ethyl}-5,5-diphenylimidazolidine-2,4-dione 
• 1418003-57-2 3-{2-[2-(benzylamino)ethoxy]ethyl}-5,5-diphenylimidazolidine-2,4-dione 
• 1418003-66-3 N-{2-[2-(2,5-dioxo-4,4-diphenylimidazolidin-1-yl)ethoxy]ethyl}aminoguanidine 
• 1418003-69-6 N,N-(butane-1,4-diyl)bis[2-(2,5-dioxo-4,4-diphenylimidazolidin-1-yl)acetamide] 
• 1418003-68-5 N,N-(propane-1,3-diyl)bis[2-(2,5-dioxo-4,4-diphenylimidazolidin-1-yl)acetamide] 
• 1418003-67-4 N,N-(ethane-1,2-diyl)bis[2-(2,5-dioxo-4,4-diphenylimidazolidin-1-yl)acetamide] 

Relevant articles and documents

Method for preparing phenytoin sodium

The invention relates to the field of biological medicines, and discloses a method for preparing phenytoin sodium. The method is characterized by comprising the following steps: (1) carrying out an oxidation reaction on benzoin in a first solvent to obtain diphenyl ethanedione, wherein the first solvent is a mixed solution of an alcohol and water, and the alcohol is at least one selected from C1-C3 monohydric alcohols; (2) carrying out a rearrangement reaction on diphenyl ethanedione to obtain phenytoin; and (3) carrying out salt forming reaction on the phenytoin in water, and performing purifying to obtain the phenytoin sodium. According to the method provided by the invention, few solvent systems are introduced, acetic acid is prevented from being used, subsequent treatment is relativelysimple, and the prepared phenytoin sodium is relatively high in yield and purity and is convenient to large-scale production.

AN IMPROVED PROCESS FOR THE PREPARATION OF PHENYTOIN SODIUM

The present invention relates to an improved process for the preparation of Phenytoin Sodium of formula (I) by reacting Phenytoin with aqueous solution of Sodium hydroxide in presence of aqueous Sodium chloride.